George Goshua
Yale University
56 Papers
18 Citations
George Goshua is an academic researcher from Yale University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 10, co-authored 18 publications.
Chat about Author
Papers
Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study.
George Goshua,Alexander B Pine,Matthew L Meizlish,C-Hong Chang,Hanming Zhang,Parveen Bahel,Audrey Baluha,Noffar Bar,Robert D Bona,Adrienne J Burns,Charles S. Dela Cruz,Anne Dumont,Stephanie Halene,John Hwa,Jonathan L. Koff,Hope Menninger,Natalia Neparidze,Christina Price,Jonathan M. Siner,Christopher A. Tormey,Henry M. Rinder,Hyung J. Chun,Alfred Ian Lee +22 more
TL;DR: The findings show that endotheliopathy is present in COVID-19 and is likely to be associated with critical illness and death, and strategies to mitigate its progression might improve outcomes in CO VID-19.
1K
A neutrophil activation signature predicts critical illness and mortality in COVID-19.
Matthew L Meizlish,Alexander B Pine,Jason Bishai,George Goshua,Emily R. Nadelmann,Michael Simonov,C-Hong Chang,Hanming Zhang,Marcus Shallow,Parveen Bahel,Kent A. Owusu,Yu Yamamoto,Tanima Arora,Deepak Atri,Amisha Patel,Rana Gbyli,Jennifer M. Kwan,Christine Won,Charles S. Dela Cruz,Christina Price,Jonathan L. Koff,Brett King,Henry M. Rinder,F. Perry Wilson,John Hwa,Stephanie Halene,William Damsky,David van Dijk,Alfred Ian Lee,Hyung J. Chun +29 more
TL;DR: In this paper, the authors carried out proteomic profiling of plasma from cross-sectional and longitudinal cohorts of hospitalized patients with COVID-19 and analyzed clinical data from a health system database of more than 3300 patients.
284
Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019: Survival and Clinical Outcomes.
Christina Price,Christina Price,Frederick L. Altice,Yu Shyr,Alan Koff,Lauren Pischel,George Goshua,Marwan M. Azar,Dayna McManus,Sheau-Chiann Chen,Shana E. Gleeson,Clemente J. Britto,Veronica Azmy,Kelsey Kaman,David C. Gaston,Matthew A. Davis,Trisha Burrello,Zachary Harris,Merceditas Villanueva,Lydia Aoun-Barakat,Insoo Kang,Stuart Seropian,Geoffrey L. Chupp,Richard Bucala,Naftali Kaminski,Alfred Ian Lee,Patricia LoRusso,Jeffrey E Topal,Charles S. Dela Cruz,Maricar Malinis +29 more
TL;DR: Tocilizumab, an IL-6 receptor antagonist, can be used to treat cytokine release syndrome (CRS), with observed improvements in a coronavirus disease 2019 (COVID-19) case series as mentioned in this paper.
200
Increased complement activation is a distinctive feature of severe SARS-CoV-2 infection
Lina Ma,Sanjaya Kumar Sahu,Marlene Cano,Vasanthan Kuppuswamy,Jamal Bajwa,Jamal Bajwa,Ja’Nia McPhatter,Ja’Nia McPhatter,Alexander B Pine,Matthew L Meizlish,George Goshua,C. Hong Chang,Hanming Zhang,Christina Price,Parveen Bahel,Henry M. Rinder,Tingting Lei,Aaron Day,Daniel Reynolds,Xiaobo Wu,Rebecca E Schriefer,Adriana M Rauseo,Charles W. Goss,Jane A. O’Halloran,Rachel M. Presti,Alfred H.J. Kim,Andrew E. Gelman,Charles S. Dela Cruz,Alfred Ian Lee,Philip A. Mudd,Hyung J. Chun,John P. Atkinson,Hrishikesh S. Kulkarni +32 more
TL;DR: In this article, the authors investigated complement activation in the plasma from patients with COVID-19 prospectively enrolled at two tertiary care centers: Washington University School of Medicine (n=134) and Yale Medical Center(n=49) and compared their patients to two non-COVID cohorts: (a) patients hospitalized with influenza and (b) patients admitted to the ICU with acute respiratory failure requiring invasive mechanical ventilation (IMV, n=22).
193
Intermediate-dose anticoagulation, aspirin, and in-hospital mortality in COVID-19: A propensity score-matched analysis.
Matthew L Meizlish,George Goshua,Yiwen Liu,Rebecca S. Fine,Kejal Amin,Eric Chang,Nicholas DeFilippo,Nicholas DeFilippo,Craig Keating,Yuxin Liu,Michael Mankbadi,Dayna McManus,Stephen Wang,Christina Price,Robert D Bona,Cassius Iyad Ochoa Chaar,Hyung J. Chun,Alexander B Pine,Henry M. Rinder,Jonathan M. Siner,Donna Neuberg,Kent A. Owusu,Alfred Ian Lee +22 more
TL;DR: In this paper, the authors examined in-hospital mortality with intermediate- compared to prophylactic-dose anticoagulation, and separately with aspirin compared to no antiplatelet therapy, in a large, retrospective study of 2785 hospitalized adult COVID-19 patients.
146